What NAION is
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms, the front of the optic nerve, which carries signals from the eye to the brain, is damaged because its blood supply drops. The result is sudden vision loss, usually in one eye, often painless and often first noticed on waking.
Some vision may return, but much of the loss is often permanent, and there is no proven treatment that reverses it. That is why even a rare link to a common medicine gets close attention. NAION was uncommon before semaglutide existed, and it is more frequent in people with diabetes, high blood pressure, sleep apnea and other conditions that are also common in people taking weight-loss medicines.
How it is diagnosed
NAION is diagnosed with an eye examination. An eye doctor looks at the optic nerve, which is usually swollen in the early days, and maps your field of vision to find the missing area. The “non-arteritic” part of the name matters: in men over 50, the doctor also needs to rule out the arteritic form, caused by inflamed arteries (giant cell arteritis), which needs urgent treatment to protect the other eye. That is one more reason sudden vision loss calls for a same-day exam rather than a wait-and-see approach.
The 2024 study that raised the question
The concern became public in July 2024, when researchers at a Boston eye hospital published a study in JAMA Ophthalmology. They reviewed records of 16,827 patients seen by neuro-ophthalmologists at one academic center between 2017 and 2023 and compared people taking semaglutide with matched patients on other medicines.
| Group | Semaglutide vs comparison | 36-month cumulative NAION | Hazard ratio |
|---|---|---|---|
| Type 2 diabetes | 194 vs 516 patients | 8.9% vs 1.8% | 4.28 |
| Overweight or obesity | 361 vs 618 patients | 6.7% vs 0.8% | 7.64 |
Those are large relative numbers, and they prompted regulators to look. The study also had real limits. It came from a single specialist center that sees people already referred for eye problems, so the rates are much higher than in the general population. It was observational, which means it could show an association but not prove cause, and the authors said so.
What the European regulator concluded
The European Medicines Agency’s safety committee, PRAC, reviewed laboratory studies, clinical trials, postmarketing reports and the published research. On June 6, 2025, it concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it.
The committee’s reasoning is worth reading closely:
- several large population studies in adults with type 2 diabetes found roughly double the risk of NAION with semaglutide;
- in absolute terms, that works out to about one additional case per 10,000 person-years of treatment;
- clinical trial data also pointed to a slightly higher risk than placebo.
The EMA recommended adding NAION to the European product information for Ozempic, Rybelsus and Wegovy. It advised that anyone with sudden vision loss or rapidly worsening eyesight on semaglutide contact a doctor without delay, and that semaglutide be stopped if NAION is confirmed.
Where US labeling stands
Regulators can weigh the same evidence differently, and the timing of label changes varies. The US Wegovy label on DailyMed, last revised in June 2026, does not list NAION among its warnings and precautions. It does include a separate warning about diabetic retinopathy complications in people with type 2 diabetes, which is a different eye problem.
Practically, the absence of a US warning does not change what you should do if your vision changes. Treat any sudden loss of vision as urgent, whatever the label says.
Eye symptoms that mean stop and call
If you take semaglutide, do not take your next dose and get seen the same day if you notice:
- sudden loss of vision in one eye, complete or partial;
- a dark shadow, blur or gray area covering part of what you see, especially the upper or lower half;
- vision that is getting worse quickly over hours or days;
- dimmer or washed-out colors in one eye compared with the other.
An eye doctor or emergency department can examine the optic nerve the same day. Call 911 instead if vision loss comes with face drooping, arm or leg weakness, confusion or trouble speaking, because those are stroke signs. After any of these, let the clinician managing your semaglutide know before restarting.
What this means for men weighing semaglutide
For most men, a risk of up to 1 in 10,000 sits well below the everyday side effects of the medicine, such as nausea, and below the health risks of untreated obesity, diabetes or heart disease. It deserves a bigger place in the decision if you already have optic nerve disease, lost vision in one eye in the past, or have several NAION risk factors at once.
Men who also use ED medicines sometimes ask about overlap. The labels for sildenafil and tadalafil mention rare reports of sudden vision loss from NAION as well, so list every medicine you take, including ones used only occasionally. Our answer on vision changes with Viagra covers that side.
Those are the men for whom an eye exam before starting, and a frank talk about alternatives, make the most sense. Our overview of semaglutide side effects puts this risk next to the common ones, and our semaglutide medication page covers how the drug works. For another warning that is often misunderstood, see our explainer on the GLP-1 thyroid cancer warning.
How Ultimate Male accounts for eye risk
Before semaglutide is considered in a medical weight loss plan, your provider asks about eye history alongside heart, thyroid and digestive history, and reviews your labs. If you have a history of optic nerve problems, we will talk through whether a different approach makes more sense, and whether to involve your eye doctor first.
If you are already on semaglutide and the NAION news worries you, a free 10-minute call is a good place to sort out whether your history puts you in a higher-risk group.
